CD226 and interstitial lung disease: We also examined the relationship between TIGIT+CD226+ CD4 T cells and clinical manifestations and observed a significantly higher frequency of this subset in DM patients with interstitial lung disease (ILD) (n = 16) than in patients without ILD (n = 14) (Fig. 1b, 26.34 ± 6.311% vs. 18.67 ± 5.614%, p = 0.0016; representative FACS plots are shown in Fig. 1c).